Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;98(14):e15001.
doi: 10.1097/MD.0000000000015001.

Weekly cisplatin for the treatment of patients with ovarian cancer: A protocol for a systematic review of randomized controlled trial

Dan-Feng Zhang  1 , Peng-Hui Dou  2 , Dong-Xu Zhao  1 , Jing Li  3 , Yu-Hong Hu  1
Affiliations

Weekly cisplatin for the treatment of patients with ovarian cancer: A protocol for a systematic review of randomized controlled trial

Dan-Feng Zhang et al. Medicine (Baltimore). 2019 Apr.

Abstract

Background: Ovarian cancer (OC) is one of the most leading causes of deaths in the Chinese women. The objective of this protocol is to perform a full-scale systematic review on the efficacy of weekly cisplatin (WC) for the treatment of patients with OC.

Methods: Data sources will comprise of PubMed, PsycINFO, Scopus, Opengrey, Cochrane Central Register of Controlled Trials, Embase, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database. All relevant randomized controlled trials from searched databases will be identified from their inception to the present. A defined search strategy will be implemented along with eligibility criteria. Relevant data will be extracted according to the predefined data collection form. Methodologic quality will be assessed by using Cochrane risk of bias tool; and data pooled and meta-analysis will be conducted by using fixed-effects, or random-effects model with RevMan 5.3 software.

Results: This proposed systematic review will evaluate the efficacy of WC for patients with OC.

Conclusion: The findings of this study may summarize the latest evidence for the WC on OC.

Ethics and dissemination: Ethical approval is not required for this study, because it will be based on published studies, and existing sources of literature. The results of this study will be disseminated through peer-reviewed journal.

Prospero registration number: PROSPERO CRD42018120938.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowchart of study selection.
See this image and copyright information in PMC

References

    1. Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol 2018;16:426–37. - PubMed
    1. Kamal R, Hamed S, Mansour S, et al. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. Br J Radiol 2018;91:20170571. - PMC - PubMed
    1. Torng PL. Clinical implication for endometriosis associated with ovarian cancer. Gynecol Minim Invasive Ther 2017;6:152–6. - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30. - PubMed

MeSH terms